Adagio Medical (ADGM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$6.7M

Net income growth (year over year)

−70.18%

Net margin

—

Return on equity

−657.76%

EPS (trailing twelve months)

−$1.37

Book value per share

−$0.02

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

101.22%

Payout ratio

—

Dividend yield

—

Company profile

Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.

• How do I buy stock in Adagio Medical (ADGM)?

  ADGM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.